whereas Binder et al. showed B1a cells to inhibit atherosclerosis. 5 The latter finding was further expanded by Kyaw et al., imputing B1a cellmediated protective effects to natural IgM antibodies produced by these cells. 6 Expanding on their previous work the same group has, in this study, explored new strategies to harness B1a cell's therapeutic potential to the treatment of atherosclerosis. 9 and regulatory T-cell recruiting CCL22 in response to apoptotic cell-exposed dsDNA, leading to tolerance induction. 10 In line, MZM depletion led to increased autoimmunity and proinflammatory cytokine production, echoing the PS liposome phenotype. Further studies will be required to conclusively establish the precise mode of action of PS liposomes in atherosclerosis. In summary, Hosseini et al. present a fresh and new therapeutic angle to tackle atherosclerosis, and by extension many other chronic inflammatory disorders. In essence, they managed to hijack a protective mechanism the body has created to avoid excess inflammation upon normal cell death. Their paper leaves us with a number of exciting questions. Firstly, will B1a cells-the key players in PS liposome-induced atheroprotection-turn out to be equally potent and PS liposome targetable in other chronic inflammatory or autoimmune diseases. Iv injected PS liposomes have been used in other animal models of arthritis 11 and myocardial infarction, 12 though their beneficial actions were in those cases entirely attributed to PS-activated phagocytic effects.
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Phosphatidylserine-induced increases in IgM production were not described, though based on the data presented here they should definitely be looked into. Secondly, the authors report a PS liposome B1a cellmediated effect on several polyreactive IgM subtypes, ensuring a broad tolerogenic response. While this offers clear opportunities for targeting other inflammatory diseases, given that natural IgMs are currently attracting considerable interest as potent immune suppressive agents, 13 such tolerogenic state could impact on host defense against tumourassociated (neo)epitopes or pathogens. Secondly, is this methodology directly translatable to a human setting? In this regard it is worth noting that IgM memory B cells have recently been proposed as the human antipode of B1a cells. Whether this subset is equally capable of mediating atheroprotective responses to PS liposome exposure will be one of the outstanding questions for the near future. Another issue relates to PS-liposome administration. Obviously ip injection is not fit for human application, but may well be critical for B1a dependent atheroprotection. Moving forward, researchers will have to find an effective way to keep the B1a cell targeting both specific as well as efficient enough, also when translated into more clinical applications. Thirdly, Hosseini et al. chose to study effects on atherosclerosis onset; studies are awaited on PS liposome effects in more advanced stages of disease. Based on the presented pilot work, a positive outcome is to Editorial be expected, and would greatly uplift the therapeutic value of their methodology. All in all, the impressive body of data presented here lays a thorough foundation for further studies into the therapeutic use of PS liposomes in the prevention of cardiovascular disease.
